Arrowhead Pharmaceuticals Price to Free Cash Flow Ratio 2010-2024 | ARWR

Arrowhead Pharmaceuticals price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as

Arrowhead Pharmaceuticals Price to Free Cash Flow Ratio 2010-2024 | ARWR

Arrowhead Pharmaceuticals price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$76.9B
Takeda Pharmaceutical (TAK)$43.9B
Merck (MKKGY)$20.8B
Astellas Pharma (ALPMY)$20.2B
Sandoz Group AG (SDZNY)$19.6B
United Therapeutics (UTHR)$17.7B
Summit Therapeutics (SMMT)$15.4B
Neurocrine Biosciences (NBIX)$12.7B
Shionogi (SGIOY)$12.3B
Catalent (CTLT)$10.9B
Madrigal Pharmaceuticals (MDGL)$7.4B
Jazz Pharmaceuticals (JAZZ)$6.9B
Orion OYJ (ORINY)$6.8B
Ionis Pharmaceuticals (IONS)$5.7B
Corcept Therapeutics (CORT)$5.7B
Crinetics Pharmaceuticals (CRNX)$4.7B
PTC Therapeutics (PTCT)$3.3B
Dyne Therapeutics (DYN)$3B
Catalyst Pharmaceuticals (CPRX)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Soleno Therapeutics (SLNO)$2.2B
NewAmsterdam Pharma (NAMS)$2B
Recursion Pharmaceuticals (RXRX)$2B
Centessa Pharmaceuticals (CNTA)$1.8B
Harrow (HROW)$1.7B
Ocular Therapeutix (OCUL)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.6B
Xencor (XNCR)$1.6B
Ardelyx (ARDX)$1.5B
ARS Pharmaceuticals (SPRY)$1.5B